Skip to main content

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

Completed · Phase 3 · NCT05462756

Conditions: Type 2 Diabetes, Type 2 Diabetes Treated With Insulin

At a glance

Research payments reported, 2025
$11,906
U.S. investigators named
3
Sites paid
3
Planned or actual enrollment
730

About the trial

Sponsor
Eli Lilly and Company
Tested
Insulin Efsitora Alfa (drug), Insulin Lispro (U100) (drug), Insulin Glargine (U100) (drug)
Dates
Started 2022-08-11; completion 2024-02-27
Results posted
Yes

The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in participants with Type 2 diabetes (T2D) that have already been treated with basal insulin and at least 2 injections per day of prandial insulin. The study consists of a 3-week screening/lead-in period, a 26-week treatment period and a 5-week safety follow-up period. The study will last up to 34 weeks.

From ClinicalTrials.gov, last updated 2025-04-27. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $11,906 in research payments for this study in 2025 (3 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Thomas Jefferson University $6,856
  • Rainier Clinical Research Center $4,500
  • Consano Clinical Research LLC $550

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.